• linkedin
  • Increase Font
  • Sharebar

    Findings reaffirm ocriplasmin success for symptomatic VMA over long term

    Treatment associated with positive efficacy, safety outcomes in 2-year randomized trial


    By Cheryl Guttman Krader; Reviewed by Pravin U. Dugel, MD

    Findings from a recent randomized trial—the Ocriplasmin (Jetrea, ThromboGenics) for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS)—provide important clues about the vitreolytic agent’s longer-term safety and efficacy and corroborate the value of careful patient selection for improving treatment success, said Pravin U. Dugel, MD.

    “The results from OASIS give us greater confidence about the MIVI-TRUST pivotal trial data,” said Dr. Dugel, managing partner, Retinal Consultants of Arizona, Phoenix, and clinical professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles.

    “We learned from OASIS that when treatment with ocriplasmin succeeds, the patients continue to do well for at least 2 years,” Dr. Dugel said.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';